Cost-Effectiveness of Blood-Based Brain Biomarkers for Screening Adults with Mild Traumatic Brain Injury in the French Health Care Setting.

Publication Year: 2022

DOI:
10.1089/neu.2022.0270

PMCID:
PMC10061334

PMID:
36267001

Journal Information

Full Title: J Neurotrauma

Abbreviation: J Neurotrauma

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Traumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Author Disclosure Statement Dr. Earnshaw and Ms. McDade are employees, and Dr. Purser was an employee, of RTI Health Solutions, a not-for-profit contract research organization that performs health outcomes research for bioMérieux and other biotechnology, pharmaceutical, and diagnostic/medical device manufacturers. Ms. Zimmer, Ms. Blanc, Dr. Textoris, Dr. Krause, and Dr. Pavlov are employees, and Dr. Beyhaghi was an employee, of bioMérieux, one of the manufacturers of the GFAP+UCH-L1 biomarkers."

Evidence found in paper:

"Funding Information This study was funded by bioMérieux, Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025